OncLive TV

Shilpa Gupta, MD, discusses challenges with ​perioperative immunotherapy in bladder cancer.

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer. 

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).

Jia Ruan, MD, PhD, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma.

Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.

Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial ​in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Sander Bach, MD, PhD, ​discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.

Nikhil C. Munshi, MD, discusses T-cell persistence with ​idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Paolo Ghia, MD, PhD, discusses updated results from the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Ursula A. Matulonis, MD, discusses the current treatment landscape in ovarian cancer.

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Heinz-Josef Lenz, MD, FACP, discusses updated efficacy data from the phase 2 CheckMate-142 trial with nivolumab plus low-dose ipilimumab in metastatic colorectal cancer.

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Marwan Fakih, MD, discusses the safety profile of AMG 510 in KRAS G12C-mutated colorectal cancer.

Solange Peters, MD,​ PhD, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer.

Muhammad Bilal Abid, MD, MRCP, discusses the current coronavirus disease 2019 pandemic and its clinical impact on patients with cancer.

C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.